ORIGINAL ARTICLE

Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis

Jun Ho Lee,1 Jae Hee Suh,2 Soo Youn Choi,1 Hyun Je Kang,1 Hwan Hee Lee,1 Byeong Jin Ye,1 Gap Ryol Lee,3 Seek Won Jung,4 Chang Jae Kim,1 Whaseon Lee-Kwon,1 Jiyoung Park,1 Kyungjae Myung,1,5 Neung Hwa Park,4 Hyug Moo Kwon1,5

ABSTRACT

Objectives  Hepatocellular carcinoma (HCC) is a common cancer with high rate of recurrence and mortality. Diverse aetiological agents and wide heterogeneity in individual tumours impede effective and personalised treatment. Tonicity-responsive enhancer-binding protein (TonEBP) is a transcriptional cofactor for the expression of proinflammatory genes. Although inflammation is intimately associated with the pathogenesis of HCC, the role of TonEBP is unknown. We aimed to identify function of TonEBP in HCC.

Design  Tumours with surrounding hepatic tissues were obtained from 296 patients with HCC who received completion resection. TonEBP expression was analysed by quantitative reverse transcription–quantitative real-time PCR (RT-PCR) and immunohistochemical analyses of tissue microarrays. Mice with TonEBP haplo deficiency, and hepatocyte-specific and myeloid-specific TonEBP deletion were used along with HCC and hepatocyte cell lines.

Results  TonEBP expression is higher in tumours than in adjacent non-tumour tissues in 92.6% of patients with HCC regardless of aetiology associated. The TonEBP expression in tumours and adjacent non-tumour tissues predicts recurrence, metastasis and death in multivariate analyses. TonEBP drives the expression of cyclo-oxygenase-2 (COX-2) by stimulating the promoter.

Conclusions  TonEBP is a key component of the common pathway in tumourigenesis and tumour progression of HCC in response to diverse aetiological insults. TonEBP is involved in multiple steps along the pathway, rendering it an attractive therapeutic target as well as a prognostic biomarker.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second most common cause of cancer-related death worldwide with steadily increasing incidence.1 The characteristic high mortality of HCC is due to a combination of multiple factors: difficulty in early detection, lack of effective treatments and extremely high rates of recurrence and metastasis.2 The major aetiological

Significance of this study

What is already known on this subject?

► Hepatocellular carcinoma (HCC) is a common cancer with high rate of recurrence and mortality. HCC is widely heterogeneous and diverse imposing formidable challenges to effective treatment and personalised therapy.

► Tonicity-responsive enhancer-binding protein (TonEBP) is a critical regulator in many inflammatory diseases such as rheumatoid arthritis and atherosclerosis. While inflammation is intimately implicated in the pathogenesis of HCC, the role of TonEBP is unknown.

What are the new findings?

► TonEBP is involved at multiple steps of the common pathway of HCC development and tumour progression: cell injury, induction by oxidative stress and inflammation.

► TonEBP stimulates hepatic inflammation including prostaglandin E2 production which contributes to tumour growth and progression.

► Expression of TonEBP is elevated in tumours in more than 90% of patients with HCC regardless of aetiology associated.

► In patients with HCC who received resection, higher hepatic TonEBP expression is associated with recurrence, metastasis and survival in multivariate analyses.

How might it impact on clinical practice in the foreseeable future?

► Examination of TonEBP expression in hepatic tissues from patients who received resection of HCC would provide the patients with valuable prognostic information regarding recurrence and metastasis.

► TonEBP is an attractive target for therapeutic agents to prevent recurrence and metastasis as well as tumourigenesis.
agents are HBV, HCV and alcoholic or non-alcoholic fatty liver. Genome sequencing, gene expression profiling and histological analyses have shown that HCC is widely heterogeneous and diverse imposing formidable challenges to effective treatment and personalised therapy.3 4

While molecular pathogenesis of HCC is multifaceted, two sequential mechanisms predominate.5 First is chronic inflammation followed by cirrhosis after tissue damage caused by viral infection, alcohol or metabolic influences. Next come mutations in oncogenes and tumour suppressor genes. Thus, a variety of aetiological insults incite common cellular reactions creating a microenvironment in which sequential mutations and genetic alterations drive formation of dysplastic nodules followed by early HCC and ultimately, metastasis. Investigating the microenvironment might uncover a common molecular pathway useful for a prognostic biomarker and therapeutic target.

Tonicity-responsive enhancer-binding protein (TonEBP), also known as NFAT5, is a central component of the inflammatory enhancosome in which TonEBP bridges activated transcription factors to histone acetyltransferase p300 on gene promoters.9 TonEBP expression is stimulated by inflammation leading to elevated expression of proinflammatory genes in rheumatoid arthritis8 and atherosclerosis.7 Although several studies have shown that TonEBP is involved in tumour cell migration,10 TonEBP’s role in tumour development and progression is unknown. In this study, we examined TonEBP in hepatic tissues obtained from patients with HCC. We found TonEBP expression to be dramatically elevated in tumours than surrounding areas regardless of aetiology in over 90% of patients with HCC confirming the general importance of inflammation. Experiments in animals revealed that TonEBP mediates the initial hepatic injury in response to environmental insults leading to local inflammation, which promotes the development and progression of HCC.

Figure 1  Hepatic TonEBP expression is elevated in HCC and associated with postoperative recurrence and death in patients with HCC. (A–D) Hepatic TonEBP expression in a mouse model of HCC. (A) TonEBP mRNA levels in tumour-free normal tissues from PBS-injected animals (n=8) and non-tumour and tumours from DEN-injected animals (n=18). Mean+SEM, *P<0.05. (B) Immunoblots of non-tumour and tumours from seven animals. (C) Immunohistochemical images of TonEBP (brown) in hepatic tissues from PBS-injected or DEN-injected animals. Nuclei were counterstained with haematoxylin (blue). (D) Tumour number and TonEBP mRNA in non-tumour in individual animals were plotted (n=12). (E–G) TonEBP expression in hepatic tissues of patients with HCC. (E) Representative immunohistochemical images of TonEBP in hepatic biopsies from patients with HCC. (F) TonEBP mRNA in non-tumour and tumour was measured from patients with HBV- (n=23), HCV- (n=7) and alcohol-associated HCC (n=8). Tumour TonEBP expression of each patient was normalised to its non-tumour region TonEBP expression. Mean+SEM, *P<0.05 compared with corresponding non-tumour. (G) Non-tumour TonEBP mRNA was measured from patients who had recurrence within 2 years of resection (solid bar, n=16) and those who did not (open bar, n=21). Mean+SEM, *P<0.05 compared with the open bar. (H) Representative images of TonEBP immunohistochemical staining of non-tumour from tissue arrays processed simultaneously. Staining intensity was assigned to five grades as shown (t0–t4). (I) Kaplan-Meier plot of postoperative recurrence in two layers of patients: tT0 (t0–1, n=80) versus tT1 (t2–4, n=166). (J) Kaplan-Meier plot of postoperative survival in two layers of patients tT0 (t0–1, n=80) versus tT1 (t2–4, n=216). (K) HEK293 cells were transfected with microRNA (miR)-223 or NC, followed by transfection of a luciferase reporter construct containing 3′-UTR of TonEBP with a putative miR-223-binding site. Luciferase activity is shown in mean+SD (n=3). *P<0.05 compared with NC. (L) HepG2 cells were transfected with miR-223 or NC followed by a 12-hour hypoxia or normoxia. TonEBP and Hsc70 immunoblotting was performed. DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; mRNA, messenger RNA; NC, non-specific control RNA; NT, non-tumour; PBS, phosphate-buffered saline; TonEBP, tonicity-responsive enhancer-binding protein; T, tumour; UTR, untranslated region.

MATERIALS AND METHODS
Human HCC samples and clinical information
A total of 296 patients who underwent hepatic resection for HCC from January 2008 to December 2015 at the Ulsan University Hospital, University of Ulsan, College of Medicine, Ulsan, Korea, were included in the study. All patients were HCC treatment naïve before surgery. All 296 patients who underwent hepatic resection had a grossly complete resection. The patients were predominantly male (84.1%), with average age of 56.6 years. The median follow-up period was 31 months.
(range = 1–105 months). Postoperative recurrence was observed in 144 cases (48.7%). The 2-year and 5-year HCC recurrence rates were 43.6% and 61.1%, respectively. During postoperative follow-up period, metastasis and death were observed in 61 (20.6%) and 84 (28.4%) of cases, respectively. Data were expressed as mean±SD or median (range). For statistical significance, Student’s t-test and χ² test were used for comparisons of variables between groups. The cumulative relapse and survival rates were evaluated by the Kaplan-Meier method, and differences were determined by the log-rank test. A multivariate analysis was carried out to identify the independent predictor for recurrence and survival using the Cox regression hazard model. All data were analysed using the statistical package SPSS for Windows V.21.0. In all cases, a two-tailed P value less than 0.05 was considered statistically significant. Additional protocols and procedures are described in online supplementary methods.

### Mice

All the methods involving live mice were carried out in accordance with the approved guidelines. All experimental protocols were approved by the Institutional Animal Care and Use Committee of the Ulsan National Institute of Science and Technology (UNISTACUC-12-15-A).

All experiments were performed in male C57BL/6 mice. To induce HCC, we administrated a single intraperitoneal injection of 25 mg/kg diethylnitrosamine (DEN) (N0756; Sigma) to 2-week-old mice and euthanised them at 9 months of age. In the obesity-amplified DEN-induced HCC model, DEN (25 mg/kg) was injected intraperitoneally into 2-week-old mice. After 4 weeks, mice were separated into two dietary groups and fed either normal diet (10% fat as kilocalories, Research Diets, New Jersey, USA) or high-fat diet (HFD; 60% fat as kilocalories, Research Diets) and euthanised for 36 weeks dietary period. Tumour incidence and size were blindly calculated.

C57BL/6 TonEBPf/f mice were bred with Alb-Cre mice or LysM-Cre to generate TonEBPf/f:Alb-Cre or TonEBPf/f:LysM-Cre, respectively. To induce liver injury, TonEBPf/f:Alb-Cre or TonEBPf/f:LysM-Cre mice and their wild type (WT) littermates were intraperitoneally injected single DEN (100 mg/kg) and euthanised after 48 hours. For lipopolysaccharide (LPS)-induced liver injury, TonEBPf/f:Alb-Cre mice were intraperitoneally injected with LPS (5 g/kg of body weight) and D-galactosamine (400 mg/kg of body weight) and euthanised after 4 hours. Ethanol feeding-induced liver injury and fat accumulation was demonstrated as described. Briefly, mice were acclimated liquid diet feeding with the control Lieber-DeCarli diet (Bio-Serv) ad libitum for 5 days, followed by ethanol Lieber-DeCarli diet (Bio-Serv) containing 5% (vol/vol) ethanol supplemented with maltose dextrin or isocaloric control diet for 10 days. To syngastically induce liver injury and inflammation, on day 11, mice were gavaged with a single dose of ethanol (5 g/kg) or isocaloric dextrin-maltose at 08:00 and sacrificed 9 hours later.

### Cell line

HCC cell line, HepG2, from American Type Culture Collection was maintained in modified Eagle’s medium (MEM; Hyclone) supplemented with 10% fetal bovine serum (FBS; Thermo) with penicillin–streptomycin (Hyclone). Cells were transfected with TonEBP small interfering (si)RNA using Lipofectamine RNAiMAX (Invitrogen) following the manufacturer’s instructions. Cells were transfected with micro-RNA (miRNA)-223 or control miRNA using Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions. Mouse embryo fibroblasts (MEFs) and HEK293 cells were cultured in Dulbecco’s MEM supplemented with 10% FBS (Thermo) with penicillin–streptomycin (Hyclone). MEFs were established from the TonEBPf/f mouse. For binding assays, HEK293 cells were transfected with plasmids using Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions. For hypoxia challenge, HepG2 cells were incubated in hypoxic chamber in 2% O₂. Additional protocols and procedures are described in online supplementary methods.

### Statistical analysis

Data are presented as means±SD or means±SEM as indicated. Differences between groups were analysed by Student’s t-test, and statistical significance was considered at *P<0.05.

### RESULTS

**Hepatic TonEBP predicts postoperative prognosis in patients with HCC**

In macrophages, TonEBP expression is markedly stimulated by inflammatory signals. Therefore inflammation is an essential feature of HCC, and we investigated hepatic TonEBP expression in DEN-induced mouse HCC. Expression ofTonEBP messenger RNA (mRNA) in non-tumour regions surrounding tumours (non-tumour TonEBP mRNA expression) was higher compared with normal hepatic tissues while lower compared with adjacent tumour (figure 1A). TonEBP expression was higher in tumours compared with non-tumour regions and localised to the nuclei of hepatocytes (figure 1B,C and online supplementary figure 1A). Interestingly, non-tumour TonEBP mRNA expression correlated significantly with tumour numbers (figure 1D) consistent with the importance of inflammation in HCC.

We examined hepatic tissues obtained from 296 patients with HCC (online supplementary table 1). As in the animals, TonEBP mRNA expression was higher in tumours compared with non-tumour regions (online supplementary figure 1B).

Immunohistochemical analyses (figure 1E and online supplementary figure 1C) revealed the same pattern of changes in 92.6% of the patients (274/296). This elevation was observed regardless of aetiology (figure 1F). Interestingly, non-tumour TonEBP mRNA expression was higher in patients who had early recurrence compared with patients who did not (figure 1G). These observations suggest importance of TonEBP in tumourigenesis, and that non-tumour TonEBP promotes postoperative recurrence.

Given the importance of TonEBP, we investigated the role of TonEBP further by stratification of the patients according to their TonEBP expression (figure 1H). Univariate analysis of two layers of patients showed that higher non-tumour TonEBP expression was significantly associated with bigger tumour, advanced tumour grade, recurrence, metastasis (ie, extrahepatic metastasis) and protein induced by higher vitamin K absence or antagonist II (PIVKA II) and HBV DNA level (online supplementary table 2). Kaplan-Meier plot confirmed the higher recurrence (figure 1I) and metastasis (online supplementary figure 2A) in patients with higher non-tumour TonEBP expression. Likewise, higher tumour TonEBP expression was associated with advanced tumour grade, microvascular invasion, recurrence, metastasis, death and higher PIVKA II level (online supplementary table 3). Again, Kaplan-Meier plot confirmed the lower survival (figure 1J) and higher metastasis and recurrence (online supplementary figure 2C,D) in patients with higher tumour TonEBP expression. These observations suggest that TonEBP promotes various aspects of tumourigenesis and progression.
We further investigated TonEBP’s role in postoperative prognosis by multivariate analyses. As for recurrence, tumour size, microvascular and lymphovascular invasion along with non-tumour TonEBP expression displayed strong association (table 1). Male sex, alanine transaminase levels, albumin levels, tumour size, tumour grade, microvascular invasion and non-tumour TonEBP expression showed robust association with metastasis. Finally, microvascular invasion, albumin levels and TonEBP expression in tumour were significantly associated with overall survival. We conclude that hepatic TonEBP expression predicts postoperative recurrence, metastasis and death in patients with HCC.

**Hepatic induction of TonEBP is mediated by a fall in the miR-223 abundance**
Elevated TonEBP expression is critical for the HCC development and progression. Previous studies showed that miR-223 expression was dramatically suppressed in HCC regardless of aetiology, likely due to local hypoxia (online supplementary figure 3A). As expected, miR-223 abundance was reduced in tumour regions compared with non-tumour regions in patients with HCC (online supplementary figure 3B) and DEN-induced HCC (online supplementary figure 3C). Since TonEBP gene is a target of miR-223 in mouse macrophages, we asked whether the hypoxia-mediated fall in miR-223 abundance was responsible for the elevated TonEBP expression. miR-223 interacted with the 3'-untranslated region of human TonEBP mRNA (figure 1K) and lowered the abundance of TonEBP (online supplementary figure 3D,E) both in normoxia and hypoxia (figure 1L). Thus, suppression of miR-223 contributes to the elevated expression of TonEBP in HCC.

**TonEBP promotes HCC initiation and growth via oxidative stress and inflammation**
Since hepatic TonEBP expression was closely associated with the number of tumours in a mouse model of HCC (figure 1D), we next investigated the role of TonEBP in HCC using a line of mice with TonEBP haplodeficiency—TonEBP*+/Δ* (figure 2A). Number of tumours and maximal tumour size were both significantly smaller in the TonEBP*+/Δ* animals than their TonEBP*+/+ littermates (figure 2B,C) in association with reduced liver injury (online supplementary table 4). Histological examinations typically revealed smaller tumours (figure 2D(i)), smaller dysplastic nodules (figure 2D(ii)) and often absence of tumours (figure 2D(iii)) in the TonEBP*+/Δ* animals. Since chronic inflammation leads to cirrhosis followed by HCC, we examined hepatic inflammation. Expression of proinflammatory and angiogenic genes was strikingly elevated in HCC mice along with TonEBP (figure 2E), indicating the association of elevated TonEBP expression with inflammation. As expected, expression of these genes was significantly lower in the TonEBP*+/Δ* animals indicating that TonEBP promoted tumour initiation and growth in association with inflammation and liver injury. In patients with HCC, the association between TonEBP and inflammation was confirmed from analysis of the RNA-seq dataset from TCGA (online supplementary figure 4).

We noted that proliferation markers were elevated in the mouse model of HCC (figure 2F,G). Inflammatory cytokines are known to promote tumour growth. Interestingly, manipulation of TonEBP expression led to parallel changes in proliferation of HepG2 cells (online supplementary figure 6B,C). Overexpression of TonEBP stimulated proliferation of neighbouring naïve cells (online supplementary figure 6D,E), suggesting that paracrine factors contributed to the TonEBP-dependent stimulation of proliferation. These results provide mechanistic basis for the role of TonEBP on the tumour growth. We conclude that TonEBP promotes tumour initiation and growth via oxidative stress-induced cell injury and inflammation.

DEN causes oxidative stress leading to hepatic cell death which, in turn, evokes local inflammation. TonEBP was induced by hypoxia (figure 1M) and H$_2$O$_2$ (online supplementary figure 5A). Knockdown of TonEBP reduced cell injury (online supplementary figure 5B,C) and inflammation (online supplementary figure 5D) in response to H$_2$O$_2$. Thus, TonEBP mediate cell injury and inflammation in response to oxidative stress.

**TonEBP is involved in obesity-induced tumour initiation and growth**
Epidemiological studies have shown that obesity increases cancer risk. Obesity-induced chronic inflammation is a major factor contributing to the increased HCC risk. Because the data discussed above showed that TonEBP promoted tumour initiation and growth via inflammation, we examined obesity-induced HCC (online supplementary figure 7A). TonEBP*+/Δ* animals were lighter than their WT littermates both in DEN-treated and PBS-treated groups up to the 12th week of HFD feeding (online supplementary figure 7B). In the DEN-treated group, distinct change took place. After the 26th week, there was a reversion where the TonEBP*+/Δ* became significantly heavier than their WT littermates because of smaller weight loss. During the reversal of body weight, high blood glucose levels in the WT littermates disappeared (online supplementary figure 7C,D). These changes are likely due to differences in tumour burden.

HFD feeding increased hepatic non-tumour TonEBP expression (figure 3A) along with more and bigger tumours (figure 3B–D), elevated expression of proinflammatory genes, proliferation markers (figure 3E) and liver injury (online supplementary table 5). TonEBP haplodeiciency was associated with fewer and smaller tumours, reduced expression of proinflammatory genes (which correlated with expression of TonEBP (figure 3F)) and proliferation markers, and milder liver injury expression providing strong evidence that TonEBP is involved in the obesity-induced inflammation and hepatocellular carcinogenesis.

**TonEBP in hepatocytes and macrophages mediates DEN-induced cellular injury and inflammation**
The data discussed above show that TonEBP promotes inflammation critical in tumour initiation and growth. Since DEN results in cellular injury leading to inflammation and eventually HCC, we examined TonEBP’s role in hepatic injury using a line of mice with hepatocyte-specific TonEBP knockout (HKO). Homic TonEBP expression, especially TonEBP immunohistochemical signal in hepatocytes, was dramatically reduced in these animals (online supplementary figure 8A,B). In WT mice, hepatic TonEBP is elevated 48 hours after DEN treatment (figure 4A) consistent with oxidative injury. DEN-induced hepatic injury was reduced in the HKO animals compared with WT littermates (figure 4B), manifest by lower terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) signal (figure 4C) and caspase-3 activity (figure 4E). Expression of Ki-67 and proliferating cell nuclear antigen (PCNA) was significantly lower in the HKO after DEN treatment along with proinflammatory genes (figure 4D,E). Phosphorylation of mitogen activated-protein kinase (MAPKs) was not affected (online supplementary...
Table 1 Univariate and multivariate analyses of postoperative recurrence, metastasis and overall survival in patients with HCC (n=296)

| Clinical variables | Recurrence | Metastasis | Overall survival |
|--------------------|------------|------------|-----------------|
|                     | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|                     | Rec (+) n=144 | Rec (-) n=152 | P value | HR (95% CI) P value | Metastasis (+) n=61 | Metastasis (-) n=235 | P value | HR (95% CI) P value | Death n=84 | Alive n=212 | P value | HR (95% CI) P value |
| Age (years)         | 57.6±9.9 | 55.7±9.7 | 0.094 | 58.0±9.9 | 56.3±9.7 | 0.224 | 0.506 | (0.271 to 0.945) | 0.032 | 69 (82.1%) | 180 (84.9%) | 0.558 |
| Male sex            | 118 (81.9%) | 131 (86.2%) | 0.318 | 46 (75.5%) | 203 (86.4%) | 0.337 | 0.506 | (0.271 to 0.945) | 0.032 | 69 (82.1%) | 180 (84.9%) | 0.558 |
| Cause of HCC        | 0.526 | 0.974 | 0.254 | 0.032 | 0.132 | 0.013 | 0.224 | 0.032 | 0.843 | 0.843 | 0.843 | 0.843 |
| Alcohol             | 14 | 13 | 0.318 | 14 | 13 | 0.318 | 0.506 | (0.271 to 0.945) | 0.032 | 69 (82.1%) | 180 (84.9%) | 0.558 |
| HBV                 | 109 | 125 | 0.506 | 109 | 125 | 0.506 | 0.506 | (0.271 to 0.945) | 0.032 | 69 (82.1%) | 180 (84.9%) | 0.558 |
| HCV                 | 16 | 9 | 0.318 | 16 | 9 | 0.318 | 0.506 | (0.271 to 0.945) | 0.032 | 69 (82.1%) | 180 (84.9%) | 0.558 |
| NAFLD               | 2 | 3 | 0.318 | 2 | 3 | 0.318 | 0.506 | (0.271 to 0.945) | 0.032 | 69 (82.1%) | 180 (84.9%) | 0.558 |
| Underdetermined     | 3 | 3 | 0.318 | 3 | 3 | 0.318 | 0.506 | (0.271 to 0.945) | 0.032 | 69 (82.1%) | 180 (84.9%) | 0.558 |
| AFP (ng/mL)         | 3290±19017 | 3011±15882 | 0.891 | 3290±19017 | 3011±15882 | 0.891 | 0.684±31684 | 1710±10786 | 0.005 | 5930±25840 | 2048±12597 | 0.084 |
| PIVKA II (mAU/mL)   | 1580±8915 | 2299±10634 | 0.549 | 1580±8915 | 2299±10634 | 0.549 | 4150±15009 | 1365±7843 | 0.057 | 3067±12679 | 1500±8404 | 0.236 |
| PT (%)              | 98.3±13.8 | 98.4±19.2 | 0.967 | 98.3±13.8 | 98.4±19.2 | 0.967 | 96.1±14.5 | 99.0±17.3 | 0.231 | 94.3±12.9 | 100.0±17.9 | 0.008 |
| PTI (10^3/mm³)      | 159±71 | 149±73 | 0.233 | 159±71 | 149±73 | 0.233 | 165±76 | 150±71 | 0.152 | 145±69.7 | 157±73.3 | 0.224 |
| ALT (IU/L)          | 46.0±33.3 | 36.6±19.9 | 0.003 | 46.0±33.3 | 36.6±19.9 | 0.003 | 35.7±19.0 | 42.6±29.3 | 0.083 | 41.5±25.1 | 41.0±26.5 | 0.887 |
| Albumin (g/dL)      | 4.15±0.42 | 4.15±0.55 | 0.843 | 4.15±0.42 | 4.15±0.55 | 0.843 | 4.06±0.43 | 4.18±0.50 | 0.111 | 3.9±0.4 | 4.3±0.5 | <0.001 |
| Total bilirubin (mg/dL) | 0.8±0.5 | 1.3±3.7 | 0.132 | 0.8±0.5 | 1.3±3.7 | 0.132 | 0.9±0.6 | 1.1±3.0 | 0.545 | 0.9±0.5 | 1.2±3.1 | 0.437 |
| MELD score          | 5.3±3.2 | 5.3±4.5 | 0.915 | 5.3±3.2 | 5.3±4.5 | 0.915 | 4.8±3.3 | 5.5±4.1 | 0.160 | 5.6±3.1 | 5.2±4.2 | 0.41 |
| CTP (A/B)           | 140/4 | 140/12 | 0.052 | 140/4 | 140/12 | 0.052 | 58/3 | 222/13 | 0.850 | 79/5 | 201/11 | 0.780 |
| Underlying liver disease (CH/LC) | 27/117 | 36/116 | 0.300 | 27/117 | 36/116 | 0.300 | 27/117 | 36/116 | 0.300 | 13/71 | 50/162 | 0.124 |
| Tumour size (cm)    | 5.1±3.0 | 4.0±3.6 | <0.001 | 5.1±3.0 | 4.0±3.6 | <0.001 | 0.587 | (0.394 to 0.875) | 0.009 | 6.3±3.9 | 4.0±3.0 | <0.001 |
| <3 cm/>3 cm         | 38±06 | 82±70 | <0.001 | 38±06 | 82±70 | <0.001 | 13/48 | 107/128 | 0.001 | 25±59 | 95±117 | 0.017 |
| Tumour number (single/multiple) | 123±11 | 131±21 | 0.850 | 123±11 | 131±21 | 0.850 | 54±7 | 200±35 | 0.495 | 72±12 | 182±30 | 0.976 |
| E-S grade (I–II/III–IV) | 59±95 | 85±67 | <0.001 | 59±95 | 85±67 | <0.001 | 14/47 | 120/115 | <0.001 | 29±55 | 105±107 | 0.019 |
| Microvascular invasion | 58/86 | 31/121 | <0.001 | 58/86 | 31/121 | <0.001 | 2.320 | (1.618 to 3.327) | <0.001 | 2.635 | 63/172 | 0.016 |
| Continued
Table 1 Continued

| Clinical variables | Recurrence | | | Metastasis | | | | Overall survival | |
|--------------------|------------|---|--------|-------------|---|--------|-------------|---|------------|---|
|                    | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|                    | HR (95% CI) | P value | HR (95% CI) | P value | Death n=84 | Alive n=212 | P value | HR (95% CI) | P value |
| Lymphovascular invasion | 37/107 | 12/140 | <0.001 | 1.856 (1.245 to 2.767) | 0.002 | 18/43 | 31/204 | 0.002 | 17/67 | 32/180 | 0.286 |
| Tumour satellites | 13/121 | 16/136 | 0.665 | 10/51 | 19/216 | 0.052 | 7/77 | 22/190 | 0.594 |
| Resection margin | 4/140 | 0/152 | 0.055 | 0/61 | 4/231 | 0.584 | 2/82 | 2/210 | 0.319 |
| Tumour capsule | 37/107 | 32/120 | 0.345 | 18/43 | 51/184 | 0.199 | 21/63 | 48/164 | 0.665 |
| Tumour septum | 48/96 | 56/96 | 0.527 | 24/37 | 80/155 | 0.440 | 31/53 | 73/139 | 0.668 |
| TonEBP expression | | | | | | | | | |
| TonEBP in non-tumour (tNT 0/1) | 48/96 | 82/70 | <0.001 | 0.566 (0.397 to 0.807) | 0.002 | 20/41 | 110/125 | 0.049 | 0.513 (0.288 to 0.914) | 0.024 | 32/52 | 98/114 | 0.204 |
| TonEBP in tumour (tT 0/1) | 29/115 | 51/101 | 0.009 | 10/51 | 70/165 | 0.036 | 15/69 | 65/147 | 0.025 | 0.547 (0.311 to 0.754) | 0.036 | |

TonT0 and tNT1 are defined in figure 1I; tT0 and tT1 are defined in figure 1J. A multivariate analysis was carried out to identify the independent predictor for recurrence and survival using the Cox regression hazard model.

AFP, alpha-fetoprotein; ALT, alanine transaminase; CH, chronic hepatitis; CTP, Child-Turcotte-Pugh class; E-S grade, Edmondson-Steiner grade; HCC, hepatocellular carcinoma; LC, liver cirrhosis; MELD score, model for end-stage liver disease score; NAFLD, non-alcoholic fatty liver disease; PIKVA II, protein induced by vitamin K absence or antagonist II; PLT, platelet; PT, prothrombin time; Rec (+), recurrence; Rec (−), non-recurrence; TonEBP, tonicity-responsive enhancer-binding protein.
Figure 2  TonEBP haplodeficiency is resistant to DEN-induced hepatocarcinogenesis. TonEBP<sup>+/Δ</sup> mice and their TonEBP<sup>+/+</sup> littermates were treated with PBS or DEN as in figure 1. (A) Non-tumour regions adjacent to tumours were immunoblotted for TonEBP and Hsc70 from DEN-injected animals. (B) Representative liver images from DEN-injected animals. (C) Tumour number, maximal size of tumours and liver weight from PBS-injected (n=8 for each genotype) or DEN-injected mice (n=18 for each genotype). Mean±SEM. #P<0.05 compared with corresponding PBS-injected animals. *P<0.05 compared with DEN-injected TonEBP<sup>+/Δ</sup> animals. (D) Representative H&E images of hepatic tissues from DEN-injected animals. Magnified images on the right are from small boxes on the left. Boxes are in tumours (top and bottom of (i)), top of (ii) and (iii), dysplastic nodule (bottom of (ii)) or tumour-free area (bottom of (iii)). (E) Real time polymerase chain reaction (RT-qPCR) analyses of TonEBP, inflammatory genes (COX-2, TNFα, IL-1β, IL-6, MCP-1), macrophage marker (F4/80), proliferation markers (Ki-67, cyclin D1) and angiogenic factors (HIF-1α, VEGF) in non-tumour regions adjacent to tumours in animals from (C). (F) Representative immunohistochemical images of TonEBP and Ki-67. COX-2, cyclo-oxygenase-2; DEN, diethylnitrosamine; HIF-1α, hypoxia-inducible factor 1 alpha; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; PBS, phosphate-buffered saline; TNFα, tumour necrosis factor alpha; TonEBP, tonicity-responsive enhancer-binding protein; VEGF, vascular endothelial growth factor.
TonEBP and MCP-1 in non-tumour areas of hepatic tissues from α(F) Correlation of TonEBP mRNA expression with mRNA expression of COX-2, TNF

Animals were shown. (D) Representative images of H&E stained liver tissues for hepatic injury and inflammation. That macrophage TonEBP also contributes to the DEN-induced hepatic injury and inflammation. (E) RT-qPCR analyses as in figure 2E. (F) Correlation of TonEBP mRNA expression with mRNA expression of COX-2, TNFα and MCP-1 in non-tumour areas of hepatic tissues from TonEBP+/+ animals fed with ND (n=10) and HFD (n=10). COX-2, cyclo-oxygenase-2; DEN, diethylnitrosamine; HFD, high-fat diet; MCP-1, monocyte chemoattractant protein 1; mRNA, messenger RNA; ND, normal diet; TNFα, tumour necrosis factor alpha; TonEBP, tonicity-responsive enhancer-binding protein.

Figure 3 Promotion of hepatocarcinogenesis by HFD is tempered by TonEBP haplodeficiency. Animals were injected with DEN as in figure 2, followed by feeding with ND or HFD for 30 weeks (online supplementary figure S7). (A) Non-tumour regions adjacent to tumours were immunoblotted for TonEBP and Hsc70 in TonEBP+/+ animals. (B) Representative liver images. (C) Top: tumour number, maximal tumour size and maximal tumour weight from individual animals fed with ND (n=12 for each genotype) or HFD (n=15 for each genotype). Mean±SEM, *P<0.05 compared with corresponding TonEBP+/+. #P<0.05 compared with corresponding ND. Bottom: tumours larger than 3 mm in diameter from representative individual animals are shown. (D) Representative images of H&E stained liver tissues from animals fed with HFD. (E) RT-qPCR analyses as in figure 2E. (F) Correlation of TonEBP mRNA expression with mRNA expression of COX-2, TNFα and MCP-1 in non-tumour areas of hepatic tissues from TonEBP+/+ animals fed with ND (n=10) and HFD (n=10). COX-2, cyclo-oxygenase-2; DEN, diethylnitrosamine; HFD, high-fat diet; MCP-1, monocyte chemoattractant protein 1; mRNA, messenger RNA; ND, normal diet; TNFα, tumour necrosis factor alpha; TonEBP, tonicity-responsive enhancer-binding protein.

TonEBP mediates LPS-induced and alcohol-induced hepatic inflammation

We asked whether TonEBP mediates inflammation induced by agents other than DEN. First, we examined LPS, which leads to hepatocyte death and inflammation.29 LPS-responsive hepatic injury (figure 4F) and inflammation (figure 4G) were tempered in the HKO. The effect of TonEBP on LPS-induced inflammation was confirmed in HepG2 cells (online supplementary figure 9A).

Alcohol causes leakage of LPS from gut into circulation leading to hepatic inflammation.30 Since alcoholic hepatitis is a risk factor for HCC, and TonEBP mediates LPS-induced hepatic injury as discussed above, the role of TonEBP in alcohol-induced hepatic injury was examined. The chronic and binge alcohol feeding resulted in hepatic damage, inflammation and fat accumulation (figure 4H–J). Hepatic injury and inflammation were reduced in the HKO animals (figure 4H,J) without significant changes in fat accumulation (figure 4F). These data demonstrate that hepatocyte TonEBP mediates alcohol-induced hepatic injury and inflammation to which the TonEBP-mediated LPS-responsive hepatic inflammation described above contributes.

To understand the role of TonEBP in hepatic inflammation in general, we analysed inflammatory stimuli-responsive inflammation. Interleukin (IL)-1β- or tumour necrosis factor alpha-induced inflammation was attenuated in TonEBP-deficient HepG2 cells (online supplementary figure 9B,C) and non-cancerous alpha mouse liver (AML)-12 cells (online supplementary figure 9D). Taken together, these data demonstrate that TonEBP is a general mediator of hepatic inflammation induced by diverse agents, consistent with elevated TonEBP expression regardless of the cause of HCC (figure 1G).

TonEBP promotes COX-2 expression in a YY1-dependent manner

Transcriptional targets of the inflammatory enhanceosome, in which TonEBP is a limiting component, include cyclo-oxygenase-2 (COX-2). We investigated COX-2 because it promotes tumourigenesis,32–34 and COX-2 expression in patients with HCC correlates with postoperative recurrence35 like TonEBP. In patients with HCC, COX-2 expression was elevated in tumour regions compared with non-tumour regions (online supplementary figure 10A). TonEBP expression correlated positively with COX-2 expression (figure 5A,B and online supplementary table 6). TonEBP deficiency resulted in reduced COX-2 expression (figure 5C,D and online supplementary figure 10B,C) leading to reduced production of prostaglandin E2 (PGE2) in various animal models (figure 5E and online supplementary figure 10D–F) and HepG2 cells (online supplementary figure 10G). Altered TonEBP expression by hypoxia and miR-223 was accompanied by parallel changes in the COX-2 expression (online supplementary figure 10H). In addition, the TonEBP-dependent stimulation of proliferation (online supplementary figure 6D,E) was dependent on COX-2 (online supplementary figure 10I). These data demonstrate that TonEBP promotes tumourigenesis and recurrence by, at least in part, the stimulation of COX-2 expression.

To understand the molecular mechanism underlying the regulation of COX-2, promoter reporters were constructed using human sequence. Initial analyses showed that TonEBP stimulated
Liver injury and inflammation are tempered by hepatocyte-specific TonEBP deficiency. (A–D) TonEBP
tt−/−, Albumin cre+/− mice (HKO) and their TonEBP
tt+/−, Albumin cre+/− (WT) littermates were injected with DEN or PBS. Livers and serum samples were analysed 48 hours later. (A) Livers from the WT animals were immunoblotted for TonEBP and Hsc70. (B) Serum ALT levels in PBS-treated (n=5) and DEN-treated animals (n=8). Mean+SEM.

TonEBP promotes YY1 recruitment to the COX-2 promoter in response to inflammation
Chromatin immunoprecipitation (ChIP) was performed to investigate the interaction of YY1 and TonEBP at the COX-2 promoter in situ. Interestingly, YY1 bound to its putative binding site of the COX-2 promoter in an IL-1β-dependent manner along with TonEBP (figure 5H) consistent with their interactions. Knockdown of TonEBP dramatically reduced of YY1 binding to the promoter (figure 5I), whereas YY1 expression (online supplementary figure 11D), nuclear translocation (online supplementary figure 11E) and binding to its promoter site (figure 5I) were not affected. Thus, YY1 binding to its cognate site in the COX-2 promoter requires TonEBP.

TonEBP is responsible for the recruitment of the histone acetyltransferase p300, a critical regulator of COX-2 transcription, to the inflammatory enhanceosome. Here, we found that YY1 interacted with p300 in HepG2 cells and the interaction showed an IL-1β responsiveness (figure 5K) as well as TonEBP dependence (figure 5L), indicating that YY1 was incorporated into the inflammatory enhanceosome on the COX-2 promoter. This observation was supported by reduced interaction between YY1 and p300 in TonEBPΔΔ MEF cells where the protein product of the TonEBPΔ allele does not interact with p300.

To characterise the interaction between TonEBP and YY1, we performed coimmunoprecipitation experiments. Overexpressed TonEBP and YY1 were mutually pulled down by each other (figure 6B). Coimmunoprecipitation with overexpressing various recombinant YY1 proteins (figure 6A) revealed that the spacer domain of YY1 was critical for the interaction with TonEBP (figure 6C). Next, Yc1, an N-terminal-truncated TonEBP with intact Rel-homology domain (RHD) (figure 6A) interacted with YY1 in a spacer-dependent manner (figure 6D), indicating that the C-terminal two-thirds of TonEBP was dispensable for the interaction. Deletion of RHD domain abolished the interaction between YY1 and YY1 (figure 6E), indicating the importance of RHD. Thus,

the COX-2 promoter without DNA binding to its cognate sites (online supplementary figure 11A,B). We hypothesised that TonEBP might be a transcriptional cofactor of a DNA-binding protein within 1 kb from the transcription start site. To identify such a protein, TonEBP-interacting proteins were identified using liquid chromatography–tandem mass spectrometry. One of the proteins picked by the procedure was the transcription factor YY1 (data not shown). We confirmed that YY1 and TonEBP were coimmunoprecipitated; plus the interactions were stimulated by IL-1β without changes in their expression (figure 5F). Knockdown of TonEBP or YY1 blunted the induction of COX-2 mRNA by IL-1β to the same extent, but the effect of double knockdown was not additive (online supplementary figure 11C). TonEBP-dependent COX-2 promoter activity was dependent on the YY1 binding site (figure 5G) demonstrating that TonEBP action required DNA binding of YY1.
the interaction between TonEBP and YY1 is mediated by RHD and spacer domain.

In summary, local inflammation stimulates the assembly of an enhancosome on the COX-2 promoter (figure 6F, bottom). This assembly is dependent on YY1 binding to its cognate site on DNA. Of interest, TonEBP is required for the recruitment of both YY1 and p300 to the promoter in situ. The critical role of TonEBP in PGE2 production provides a mechanistic basis for the YY1–DNA complex (right). (K) Lysates of HepG2 cells transfected with siRNA indicated followed by transfection with pGL3 (vector), COX-2 (COX-2 promoter reporter in pGL3) or ΔYY1 (COX-2 whose YY1 binding site was disabled by mutagenesis) (n=3). (H) HepG2 cells were treated with IL-1β as indicated. ChIP was performed using anti-TonEBP serum (T), normal serum (S) or anti-YY1 serum (Y). The immunoprecipitates and cell lysates were immunoblotted as indicated. (G) HepG2 cells were transfected with siRNA indicated followed by transfection with pgl3 (vector), COX-2 (COX-2 promoter reporter in pGL3) or ΔYY1 (COX-2 whose YY1 binding site was disabled by mutagenesis) (n=3). (J) Nuclear extracts were prepared from HepG2 transfected with siRNA follow by treatment with IL-1β as indicated. Electrophoretic mobility shift assay was performed (see supplementary material and methods). Anti-YY1 IgG or normal IgG was used to supershift the YY1–DNA complex (right). (K) Lysates of HepG2 cells treated with IL-1β were immunoprecipitated. Lysates and immunoprecipitates were immunoblotted for p300 and YY1. (L) Cells transfected with siRNA were immunoprecipitated as above. (M) MEFs from TonEBP+/Δ and TonEBPΔ/Δ mice (Δ/Δ) were immunoprecipitated. ChIP, chromatin immunoprecipitation; COX-2, cyclo-oxygenase-2; DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; IL, interleukin; MEF, mouse embryo fibroblast; mRNA, messenger RNA; PBS, phosphate-buffered saline; PGE2, prostaglandin E2; siRNA, small interfering RNA; TonEBP, tonicity-responsive enhancer-binding protein.

**DISCUSSION**

Given that HCC is a heterogeneous disease with diversity in aetiological agents, tumour architectures, histological characteristics, repertoire of oncogenic mutations and gene expression profiles, it is remarkable that elevated TonEBP expression in tumours over non-tumour regions is observed in more than 90% of patients with HCC. TonEBP is more prevalent than any other immunohistochemical biomarker of HCC and the first one associated with inflammation. The widespread elevation in tumour TonEBP levels demonstrates that inflammation is the common feature of heterogeneous HCC. In the cohort of patients with HCC studied here, higher tumour TonEBP expression predicts death and is associated with tumour size, grade, recurrence and metastasis. COX-2 expression is driven by the elevated TonEBP leading to the production of PGE2, which promotes tumourigenesis and progression, providing a mechanistic basis for the TonEBP as a part of the common pathway activated by the diverse aetiological agents (figure 6F).

Hepatic resection has been the treatment of choice for early HCC. However, resection is associated with a 70% recurrence rate in the remaining hepatic tissue. Postoperative recurrence is classified as early or late depending on whether the recurrence occurs within 2 years of resection or not. Remarkably, TonEBP mRNA expression was higher in the non-tumour regions of patients who had early recurrence compared with those who did not. In the cohort of patients with HCC, higher non-tumour TonEBP expression predicts recurrence and metastasis and is associated with tumour size and grade. We observe COX-2 expression is also driven by TonEBP in this region. PGE2 is known to educate inflammatory tumour microenvironment to promote tumour...
Figure 6  TonEBP and YY1 interact via RHD and spacer. (A) Diagrams of TonEBP and YY1 and their deletion constructs. (B–E) Lysates from HEK293 cells transfected with Myc-TonEBP plus Flag-YY1 (B) or various recombinant fragment of Flag-YY1 (C), Myc-Y1 plus or Flag-YY1 or Flag-YY1-D5 (D) or Flag-YY1 plus Myc-TonEBP or Myc-TonEBP-RHD (E) were immunoprecipitated with normal IgG, anti-Flag IgG or anti-Myc IgG as indicated. The immunoprecipitates (upper) and lysates (bottom) were immunoblotted as indicated. (F) Model of TonEBP actions in the pathogenesis of HCC. First, TonEBP mediate oxidative stress-induced cell injury and local inflammation. Second, TonEBP expression is enhanced by oxidative stress. On the promoter of the COX-2 gene, the elevated TonEBP recruits the acetyltransferase p300 to YY1 in a manner dependent on IL-1β. TonEBP promotes tumorigenesis, recurrence and metastasis via PGE2, and possibly other pathways (broken line). See text for details. COX-2, cyclo-oxygenase-2; Flag, anti-Flag IgG; GA rich, glycine-alanin rich; GK rich, glycine-lysine rich; HCC, hepatocellular carcinoma; IB, immunoblot; IgG, normal IgG, Myc, anti-Myc IgG; PGE2, prostaglandin E2; RHD, Rel-homology domain; TonEBP, tonicity-responsive enhancer-binding protein.

Progression by orchestrating crosstalk between tumour cells and their microenvironment. Thus, the TonEBP–COX-2–PGE2 pathway contributes to recurrence. Given the complexity of cellular mechanisms involved in recurrence, we suspect that there might be other pathways of TonEBP such as cell migration that contribute to recurrence (figure 6F).

Studies in various mouse models of HCC and hepatitis reveal additional TonEBP actions upstream of inflammation. The diverse insults that cause HCC impose oxidative stress leading to cell injury and inflammation. Experiments with TonEBP-deficient animals and cultured hepatocytes demonstrate that TonEBP promotes the cell injury and inflammation in response to oxidative stress (figure 6F). In addition, TonEBP expression is dramatically elevated in response to oxidative stress providing a positive reinforcement. Thus, TonEBP is intrinsically involved in multiple steps in the cellular pathways stimulated by the various insults that cause HCC. This explains the strong association of hepatic TonEBP and poor prognosis in patients with HCC. On the other hand, since our patient cohort is heavily biased to HBV-driven HCC, the association needs more robust verification in patients with other aetiologies.

The data presented here suggest that targeting TonEBP is an attractive strategy to prevent recurrence as well as hepatocarcinogenesis and metastasis. In this regard, three distinct action sites of TonEBP can be considered (figure 6F): (1) cell injury and inflammation; (2) induction of TonEBP by oxidative stress and downregulation of miR-223 and (3) transriptional stimulation of COX-2 and other proinflammatory genes. We reported that a small compound cerulenin inhibited the transcriptional stimulation of proinflammatory genes including COX-2 by blocking the interaction of TonEBP and p300. We find that cerulenin blocks the IL-1β–induced transcription of COX-2 in hepatocytes (data not shown). Cerulenin and other agents that target any of the three sites of TonEBP action might be proved efficacious in preventing recurrence and metastasis for patients with HCC whose hepatic TonEBP expression is high.

Acknowledgements  We thank the patients who generously provided tissues in our studies. Dr Neuhofer provided TonEBP floxed mice. Jin Hoi Hur assisted in the microscope-associated work.

Contributors  JHL, NHP and HMK conceived, designed, performed and analysed most of the experiments. SY contributed to the performance experiments. JHS performed histological analysis and performed and analysed tissue array and immunohistochemical analysis. JHH, BWS and JWH contributed to the performance experiments. GRL provided YY1 constructs. KM, WJ and JP provided intellectual input. NHP and HMK supervised experiments.

Funding  This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT) (NRF-2011-0020163, NRF-2010-0029621, NRF-2016R1A1A03003235, NRF-2012R1A1A02043693, NRF-2017R1E1A01074673), Health Technology R&D Project grant of Korea (HI16C1837) and the Institute for Basic Science (IBS-R022-D1-2016) of Korea. This work was also supported by UNIST fund (1.170068.01). JHL was supported by Global PhD Fellowship of Korea (NRF-2014H1A2A1019656).

Competing interests  None declared.

Patient consent  Obtained.

Ethics approval  This research was approved by the Institutional Review Board at the UlSAN University Hospital (UUN 2015-12-018).

Provenance and peer review  Not commissioned; externally peer reviewed.

Open Access  This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,
REFERENCES
1. Fornier A, Briax J. Biomarkers for early diagnosis of hepatocellular carcinoma. *Lancet Oncol* 2012;13:750–1.
2. El-Serag HB. Hepatocellular carcinoma. *N Engl J Med* 2011;365:1118–27.
3. Quarrardt JU, Andersen JH, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. *Nat Rev Cancer* 2015;15:653–67.
4. Caldero J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. *J Hepatol* 2017;67:727–38.
5. Whittaker S, Marquardt JU, et al. Liver cancer: recent advances and future potential. *Nat Rev Cancer* 2017;17:234–49.
6. Olschwang S, Gatti J, et al. Long-term follow-up of survival after resection of hepatocellular carcinoma. *Hepatology* 2011;54:229–37.
7. Forner A, Reig M, et al. Hepatocellular carcinoma: recent advances and future perspectives. *Lancet* 2018;391:1309–23.
8. Marini P, Capussotti L, et al. Treatment of hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2012;9:201–11.
9. Kondo T, Wang Z, et al. A novel anti-TLR7 mAb with potent antiviral and antitumor effects. *J Clin Invest* 2014;124:3567–79.
10. Reckamp KL, et al. Nivolumab for recurrent or metastatic nasopharyngeal carcinoma. *Nat Rev Cancer* 2017;17:418–29.
11. Kato Y, et al. NaPi-2b trafficking and localization in human hepatocellular carcinoma. *Hepatology* 2012;55:1664–76.
12. Go WY, Liu X, Rott MA, et al. NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment. *Proc Natl Acad Sci U S A* 2004;101:10673–8.
13. Alderton GK. Inflammation: the gut takes a toll on liver cancer. *Nat Rev Cancer* 2012;12:379–79.
14. Yoon HJ, et al. NFAT5 is expressed in hepatic stellate cells in chronic hepatitis C. *Gastroenterology* 2006;131:1658–66.
15. Aoki Y, et al. Liver injury and survival in mice treated with a diet containing 1-methyl-1-nitrosourea. *Carcinogenesis* 2013;34:2741–49.
16. Deng W, et al. A novel anti-TLR7 mAb with potent antiviral and antitumor effects. *J Clin Invest* 2014;124:3567–79.
17. Fan X, He C, Jiao W, et al. Mannose receptor is a critical regulator of inflammatory arthritis. *J Immunol* 2017;198:4063–75.
18. Wu J, et al. Proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. *Cancer Res* 2012;72:3977–86.
19. Bianchini F, et al. Macrophage-derived IL-10 regulates alternative macrophage activation. *Exp Toxicol Pathol* 2014;66:429–36.
20. Yoon HJ, et al. TNFα and proinflammatory cytokines in the pathogenesis of hepatocellular carcinoma. *World J Gastroenterol* 2013;19:1995–2001.
21. Buxade M, et al. Gene expression induced by Toll-like receptors in macrophages requires the transcription factor NFAT5. *J Exp Med* 2012;209:379–93.
22. Starley BQ, et al. The role of NFAT5 transcription factors in inflammatory arthritis. *Arthritis Rheum* 2011;63:1843–52.
23. Schirmer M, et al. NFAT5 regulates alternative macrophage activation. *J Clin Invest* 2017;127:954–69.
24. Haltermann JA, et al. NFAT5 expression in bone marrow-derived cells enhances osteoclastogenesis and drives macrophage migration. *Front Physiol* 2012;3:313.
25. Jauliac S, et al. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. *Nat Cell Biol* 2002;4:540–4.
26. Küber C, Beck FK, Neuhofer W. Generation of a conditional knockout allele for the NFAT5 gene in mice. *Nat Protoc* 2011;6:507.
27. Bertola A, et al. Mouse model of chronic and binge ethanol feeding (the NIAAA model). *Nat Protoc* 2013;8:627–37.
28. Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;420:860–7.
29. Elnav E, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. *Nat Rev Cancer* 2013;13:759–71.
30. Wong OW, Lung RW, Law PT, et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stat3/1. *J Gastroenterol* 2008;43:135–57.
31. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. *N Engl J Med* 2011;364:656–65.
32. Nath B, Szabo G. Hypoxia and hypoxia-inducible factors: diverse roles in liver diseases. *Hepatology* 2012;55:622–33.
33. Ying W, Tseng A, Chang RC, et al. MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation. *J Clin Invest* 2015;125:4149–59.
34. Go WY, Liu X, Rott MA, et al. NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment. *Proc Natl Acad Sci U S A* 2004;101:10673–8.
35. Alderton GK. Inflammation: the gut takes a toll on liver cancer. *Nat Rev Cancer* 2012;12:379–79.